Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients
Frontiers in Public Health · 07.12.2023 · 11
DOI: 10.3389/fpubh.2023.1196789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 07.12.2023. Verfasst von Lei Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Heart Failure, Hyperkalemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Hyperkalemia most commonly develops in chronic kidney disease (CKD) or heart failure (HF) patients. Sodium zirconium cyclosilicate (SZC) is a new selective potassium (K+) binder for treating hyperkalemia. The aim of this study was to evaluate the cost-effectiveness of SZC vs. usual care for the treatment of hyperkalemia among CKD patients or HF patients in China.
Methods
Individual patient microsimulation models were constructed to simulate a CKD cohort until the initiation of renal replacement therapy (RRT) and a HF cohort across the lifetime horizon. K+ levels were based on two phase 3 clinical trials. Health state utility and event incidence rates were retrieved from literature. Drug costs and healthcare utilization costs were obtained from negotiated price, literature, and expert interviews. Costs and quality-adjusted life-years (QALYs) were both discounted at 5%. The main outcomes were overall costs, QALYs, and incremental cost-effectiveness ratio (ICER). The willingness-to-pay (WTP) threshold in China is CNY 80,976-242,928/QALY, which is one to three times the gross domestic product per capita . Sensitivity analyses were performed to characterize the models’ uncertainty.
Results
In the HF cohort, the base case results revealed that SZC was associated with 2.86 QALYs and the total cost was CNY 92671.58; usual care was associated with 1.81 QALYs and CNY 54101.26. In the CKD cohort, SZC was associated with 3.23 QALYs and CNY 121416.82 total cost; usual care was associated with 2.91 QALYs and CNY 111464.57. SZC resulted in an ICER of CNY 36735.87/QALY for the HF cohort and CNY 31181.55/QALY for the CKD cohort, respectively. The one-way and probability sensitivity analyses found that the results were robust.
Conclusion
SZC is a cost-effective treatment compared to usual care in HF and CKD patients. SZC is an important novel treatment option for managing patients with hyperkalemia in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Zitieren
APA
Tian, L., Fu, S., Li, M., Zhao, X., & Li, H. (2023). Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1196789
Vancouver
Tian L, Fu S, Li M, Zhao X, Li H. Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients. Frontiers in Public Health. 2023;11. doi:10.3389/fpubh.2023.1196789
BibTeX
@article{Tian2023,
author = {Tian, Lei and Fu, Shihui and Li, Mengyuan and Zhao, Xinrui and Li, Hongchao},
title = {Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients},
journal = {Frontiers in Public Health},
year = {2023},
volume = {11},
doi = {10.3389/fpubh.2023.1196789}
}
EUVIMED